SCI & TECH● LOW1h ago · Sep 30, 2026, 2:32 PM
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC · global
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH39m agoA Viper That Caused Alarm in California Was A.I.-GeneratedNYT USSCI & TECH53m agoAre techbros afraid of AI?La Silla VacíaSCI & TECH53m agoDebunking political fearmongering over data centersThe HillSCI & TECH54m agoFTC is investigating OpenAI, Anthropic and other AI companies over product risksCNBC